237 related articles for article (PubMed ID: 19707688)
1. In silico study of MMP inhibition.
Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
[TBL] [Abstract][Full Text] [Related]
2. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction.
Hu X; Shelver WH
J Mol Graph Model; 2003 Nov; 22(2):115-26. PubMed ID: 12932782
[TBL] [Abstract][Full Text] [Related]
3. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
[TBL] [Abstract][Full Text] [Related]
4. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
5. Quantum chemical study on the coordination environment of the catalytic zinc ion in matrix metalloproteinases.
Díaz N; Suarez D; Sordo TL
J Phys Chem B; 2006 Nov; 110(47):24222-30. PubMed ID: 17125395
[TBL] [Abstract][Full Text] [Related]
6. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
7. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
8. In situ "click" assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups.
Hu M; Li J; Yao SQ
Org Lett; 2008 Dec; 10(24):5529-31. PubMed ID: 19053720
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
10. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
[TBL] [Abstract][Full Text] [Related]
11. Making a new turn in matrix metalloprotease inhibition.
Wasserman ZR
Chem Biol; 2005 Feb; 12(2):143-4. PubMed ID: 15734640
[TBL] [Abstract][Full Text] [Related]
12. QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives.
Fernández M; Caballero J
Bioorg Med Chem; 2007 Sep; 15(18):6298-310. PubMed ID: 17590339
[TBL] [Abstract][Full Text] [Related]
13. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
14. Ternary ligand-zinc-hydroxamate complexes.
Chiu YH; Gabriel GJ; Canary JW
Inorg Chem; 2005 Jan; 44(1):40-4. PubMed ID: 15627358
[TBL] [Abstract][Full Text] [Related]
15. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.
Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A
Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045
[TBL] [Abstract][Full Text] [Related]
16. Computational investigation of irreversible inactivation of the zinc-dependent protease carboxypeptidase A.
Cross JB; Vreven T; Meroueh SO; Mobashery S; Schlegel HB
J Phys Chem B; 2005 Mar; 109(10):4761-9. PubMed ID: 16851559
[TBL] [Abstract][Full Text] [Related]
17. Selective non zinc binding inhibitors of MMP13.
De Savi C; Morley AD; Ting A; Nash I; Karabelas K; Wood CM; James M; Norris SJ; Karoutchi G; Rankine N; Hamlin G; Macfaul PA; Ryan D; Baker SV; Hargreaves D; Gerhardt S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4215-9. PubMed ID: 21669521
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations of matrix metalloproteinase 2: role of the structural metal ions.
Díaz N; Suarez D
Biochemistry; 2007 Aug; 46(31):8943-52. PubMed ID: 17616173
[TBL] [Abstract][Full Text] [Related]
19. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
20. Factors governing the protonation state of Zn-bound histidine in proteins: a DFT/CDM study.
Lin YL; Lim C
J Am Chem Soc; 2004 Mar; 126(8):2602-12. PubMed ID: 14982470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
